<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00114933</url>
  </required_header>
  <id_info>
    <org_study_id>SPA-378-05-40</org_study_id>
    <secondary_id>EudraCT 2004-001323-37</secondary_id>
    <nct_id>NCT00114933</nct_id>
  </id_info>
  <brief_title>&quot;OK 2004 Study&quot; (Only Kaletra 2004 Study): Study to Evaluate Suspending Nucleosides From Triple-Drug Therapy in HIV Subjects</brief_title>
  <official_title>Phase III-IV, Comparative, Randomized, Open-Label, Study to Evaluate Safety and Efficacy of Suspending Nucleosides From a Triple-Drug Therapy Based on Lopinavir/Ritonavir Versus Continuing Triple-Drug Therapy in HIV-Infected Subjects With Undetectable Plasma HIV Viremia for Six Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arribas, Jose R., M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pulido, Federico, M.D.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Arribas, Jose R., M.D.</source>
  <brief_summary>
    <textblock>
      Lopinavir/ritonavir monotherapy may maintain virologic suppression in patients who have been
      undetectable for six months while on triple drug antiretroviral therapy. Lopinavir/ritonavir
      pharmacokinetics might prevent resistance development in patients who experience virological
      rebound after single-drug simplification.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Study Objective: Efficacy and durability of switching to lopinavir/ritonavir
      single-drug HAART compared to maintaining therapy based on lopinavir/ritonavir and two
      nucleosides

      Secondary Study Objective(s):

        -  Safety (related drug AEs/SAEs and laboratory anomalies G3/4) through 48 w.

        -  Resistance profile on patients with sustained virological failure

        -  QOL comparing stopping nucleosides versus continuing therapy

        -  Pharmaco-economic analysis comparing treatment cost between the 2 study arms.

        -  Predicting factors of failure in the stopping nucleosides arm

      Subject Population: 200 patients

      Study Design:

      RANDOMIZATION:

      Patients are randomized (1:1) either to continue under the same treatment or stop nucleosides
      as follows:

        -  Stopping nucleosides arm: Lopinavir/r alone.

        -  Continuing arm: Lopinavir/r + 2 NRTIs

      STUDY PROCEDURES: A baseline HIV-RNA, CD4 and routine labs will be collected if the most
      recent results are not collected within the 4 weeks prior entering the study. Patients will
      be followed for HIV-RNA (and CD4) at w1, w4, w8, w16, w24, w 36 and w48. After w48,
      durability of response to lopinavir/r single-drug therapy will be studied long-term (up to
      w96). Routine hematology and clinical chemistry (including fasting triglycerides and
      cholesterol, total and HDL/LDL ratio) will be measured at w4, w16, w24, w 36 and w48. A
      central laboratory will be used for HIV-RNA determinations and to archive plasma/cell samples
      for further genotype test in case of rebound.

      Treatment adherence will be followed with a self-patient report questionnaire (GEEMA study)

      All AEs will be collected if suspected relation (possible or probable) to any concomitant ARV
      drug, and SAEs, related or not, reported within 24h.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date>May 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>% patients with therapeutic failure in both arms at 48 weeks (OT and ITT)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>% patients with virological failure: HIV-RNA &gt; 500 cop/ml under the randomly assigned therapy (OT and ITT)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% patients with HIV RNA &lt; 500 cop/ml and &lt; 50 cop/ml at w24, w48 (OT and ITT)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to virological failure per Kaplan Meyer analysis</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 cell count change from baseline</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of viruses with resistance in the protease gene at w24 and w48</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of AEs with probable, possible or unknown relationship to study drug</measure>
  </secondary_outcome>
  <enrollment>200</enrollment>
  <condition>HIV Infection</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stopping nucleosides and continuing lopinavir/ritonavir monotherapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV patients &gt; 18 years old who provide signed and dated Informed consent.

          -  HIV patients who have been receiving lopinavir/ritonavir and two nucleosides during at
             least 4 weeks.

          -  Plasma HIV RNA &lt; 50 cop/ml for six months

        Exclusion Criteria:

          -  HIV patients who have stopped a protease inhibitor due to virological failure.

          -  HIV patients with hepatic or renal insufficiency.

          -  HIV patients with positive serum HBVAg

          -  HIV patients who require treatment with a lopinavir/r contraindicated medication.

          -  HIV pregnant or breastfeeding women.

          -  Active drug abuse (including alcohol or recreational drugs). Exception, cannabis,
             provided the investigator is confident in patient adherence. Patients under Methadone
             program will be accepted too if deemed appropriate by the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José R. Arribas, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital La Paz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Federico Pulido, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital 12 de Octubre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital General de Elche</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03202</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Bellvitge</name>
      <address>
        <city>Hospitalet de LLobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Insular</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <state>Gran Canaria</state>
        <zip>35500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Donostia</name>
      <address>
        <city>San Sebastián</city>
        <state>Guipuzcoa</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital U. Príncipe de Asturias</name>
      <address>
        <city>Alcalá de Henares</city>
        <state>Madrid</state>
        <zip>28880</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Xeral Cies</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>362004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <state>Tenerife</state>
        <zip>38010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Basurto</name>
      <address>
        <city>Bilbao</city>
        <state>Vizcaya</state>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28 046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nuestra Señora de Valme (Sevilla)</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Dr. Peset</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2005</study_first_submitted>
  <study_first_submitted_qc>June 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2005</study_first_posted>
  <last_update_submitted>March 20, 2008</last_update_submitted>
  <last_update_submitted_qc>March 20, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 21, 2008</last_update_posted>
  <keyword>HIV</keyword>
  <keyword>AIDS</keyword>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

